drugset

drugset / Trial / NCT05905614

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

NCT05905614 ↗

Phase 1/2 Completed 29 enrolled Shanghai Pharmaceuticals Holding Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.

Timeline

Start: 2020-11-03
Primary completion: 2023-10-26
Completion: 2023-10-26

Publications

Jiang Y, Liang X, Sun ML, Gao G, Gong Y, Li HP, Liu J, Wang YS. Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors. Oncologist. 2025 Jun 4;30(6):oyaf077. doi: 10.1093/oncolo/oyaf077.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPH4336	Unknown	—	Oral

Indications